Sökning: onr:"swepub:oai:lup.lub.lu.se:019baa84-5f5b-461f-b901-d4c15d885e33" >
Effects of formoter...
Effects of formoterol (Oxis (R) Turbuhaler (R)) and ipratropium on exercise capacity in patients with COPD
-
Liesker, JJW (författare)
-
Van de Velde, V (författare)
-
Meysman, M (författare)
-
visa fler...
-
Vincken, W (författare)
-
- Wollmer, Per (författare)
- Lund University,Lunds universitet,Klinisk fysiologi och nuklearmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Physiology and Nuclear Medicine, Malmö,Lund University Research Groups
-
- Hansson, Lennart (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Kerstjens, HAM (författare)
-
Qvint, U (författare)
-
Pauwels, RA (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2002
- 2002
- Engelska.
-
Ingår i: Respiratory Medicine. - : Elsevier BV. - 1532-3064 .- 0954-6111. ; 96:8, s. 559-566
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium significantly improved TTE, FEV1, FEF25-75%, FRC, IVC, RV and sGAW compared with placebo. A negative dose-response relationship was observed with formoterol. Ipratropium increased time to exhaustion more compared with formoterol, 18 mug, but not with formoterol, 4.5 and 9 mug. No changes in Borg score were found. There was no difference in the adverse event profile between treatments. In conclusion, I week of treatment with formoterol and ipratropium significantly improved exercise capacity and lung function compared with placebo. However, a negative dose-response relation for formoterol was unexpected and needs further investigation.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- exercise capacity
- formoterol
- COPD
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas